Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure
PeerJ · 2024
DOI: 10.7717/peerj.18595 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PeerJ, 2024. Verfasst von Tuong Le Trong Huynh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam. Hauptthemen laut MEDLINE: Uric Acid, Losartan, Benzhydryl Compounds, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed.
Objective
Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients.
Methods
We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value.
Results
After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being −229.62 ± 76.65 µmol/L, −217.00 ± 146.17 µmol/L, and −284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from −226.21 ± 74.65 µmol/L to −231.85 ± 76.28 µmol/L and −209.62 ± 184.94 µmol/L to −225.75 ± 78.53 µmol/L and −273.02 ± 204.54 µmol/L to −308.93 ± 72.97 µmol/L in group A, B, and C, respectively.
Conclusion
The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.
- Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam.
Zitieren
APA
Huynh, T. L. T., Pham, P. T., Tran, H. D., Tran, N. D., Tran, D. V., Tran, B. L. T., Tran, K. D. D., Ngo, T. H., & Tran, S. K. (2024). Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure. PeerJ. https://doi.org/10.7717/peerj.18595
Vancouver
Huynh TLT, Pham PT, Tran HD, Tran ND, Tran DV, Tran BLT, et al. Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure. PeerJ. 2024. doi:10.7717/peerj.18595
BibTeX
@article{Huynh2024,
author = {Huynh, Tuong Le Trong and Pham, Phong Thanh and Tran, Hien Dieu and Tran, Nhan Dinh and Tran, Duong Van and Tran, Bao Lam Thai and Tran, Khoa Dang Dang and Ngo, Toan Hoang and Tran, Son Kim},
title = {Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.18595}
}
EUVIMED